16.78

2.75% 0.388

Neuropace Inc (NPCE)

Overview News Price History Financials Discussions Forecast

Neuropace Inc stock is traded at $16.78, with a volume of 472.58K. It is up +2.75% in the last 24 hours and up +2.68% over the past month. NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Previous Close:

$16.39

Open:

$16.39

24h Volume:

472.58K

Relative Volume:

2.20

Market Cap:

$558.57M

Revenue:

$65.42M

Net Income/Loss:

$-32.96M

P/E Ratio:

-13.21

EPS:

-1.27

Net Cash Flow:

$-19.87M

1W Performance:

+9.07%

1M Performance:

+2.68%

6M Performance:

+64.77%

1Y Performance:

+35.59%

1-Day Range:

$16.22

$17.39

1-Week Range:

$15.03

$17.39

52-Week Range:

$7.5625

$18.98

Neuropace Inc Stock (NPCE) Company Profile

Name

Neuropace Inc

Sector

Healthcare (1120)

Industry

Medical Devices (141)

Phone

(650) 237-2700

Address

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Employee

209

Twitter

Next Earnings Date

2025-03-04

Latest SEC Filings

NPCE's Discussions on Twitter

Compare NPCE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NPCE Neuropace Inc	16.77	545.91M	65.42M	-32.96M	-19.87M	-1.27
ABT Abbott Laboratories	127.03	222.19B	43.84B	13.90B	6.92B	7.9725
BSX Boston Scientific Corp	98.64	144.97B	19.35B	2.78B	3.82B	1.8696
SYK Stryker Corp	367.64	140.12B	24.38B	2.94B	4.07B	7.6159
MDT Medtronic Plc	99.78	128.60B	34.76B	4.79B	5.21B	3.7017
EW Edwards Lifesciences Corp	84.67	49.82B	5.88B	1.34B	799.60M	2.3489

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-25	Initiated	H.C. Wainwright	Buy
Jan-21-25	Initiated	UBS	Buy
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-30-24	Initiated	Leerink Partners	Outperform
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-22-23	Initiated	Lake Street	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform
May-17-21	Initiated	JP Morgan	Overweight
May-17-21	Initiated	Morgan Stanley	Overweight
May-17-21	Initiated	SVB Leerink	Outperform
May-17-21	Initiated	Wells Fargo	Overweight

View All

Neuropace Inc Stock (NPCE) Latest News

Jan 06, 2026

Why NeuroPace Inc. stock remains undervalued2026 world cup usa national team round of 16 defensive leaders pressing system knockout prediction breakdown - ulpravda.ru

Jan 06, 2026

NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat

Jan 06, 2026

UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - MSN

Jan 06, 2026

Jan 01, 2026

Responsive Playbooks and the NPCE Inflection - Stock Traders Daily

Jan 01, 2026

Dec 31, 2025

FOMO Trade: Is NeuroPace Inc stock oversold or undervalued2025 Pullback Review & Low Risk High Win Rate Picks - moha.gov.vn

Dec 31, 2025

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire

Dec 31, 2025

Dec 28, 2025

Is NeuroPace Inc. stock a buy on dipsPrice Momentum Alerts & Grow Steadily With Our Wealth Roadmap - bollywoodhelpline.com

Dec 28, 2025

Dec 25, 2025

Published on: 2025-12-25 19:47:27 - moha.gov.vn

Dec 25, 2025

Dec 22, 2025

NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 22, 2025

Dec 21, 2025

Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily

Dec 21, 2025

Dec 20, 2025

How resilient is NeuroPace Inc. stock in market downturns2025 Market WrapUp & Long Hold Capital Preservation Tips - bolumsonucanavari.com

Dec 20, 2025

Reviewing NeuroPace (NASDAQ:NPCE) & PROCEPT BioRobotics (NASDAQ:PRCT) - Defense World

Dec 20, 2025

Dec 19, 2025

Why NeuroPace Inc. stock attracts global investorsInflation Watch & Weekly Watchlist for Hot Stocks - Улправда

Dec 19, 2025

How NeuroPace Inc. stock performs in rate cut cycles2025 Earnings Impact & Weekly Watchlist for Consistent Profits - DonanımHaber

Dec 19, 2025

Is NeuroPace Inc. stock attractive for growth ETFs2025 Buyback Activity & Risk Controlled Daily Plans - Улправда

Dec 19, 2025

Can NeuroPace Inc. stock deliver sustainable ROEWatch List & Fast Entry and Exit Trade Plans - Улправда

Dec 19, 2025

Is NeuroPace Inc. stock oversold or undervaluedTrade Exit Report & Expert Curated Trade Ideas - DonanımHaber

Dec 19, 2025

Will NeuroPace Inc. stock outperform growth indexes2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда

Dec 19, 2025

Will NeuroPace Inc. stock benefit from green energy trendsWeekly Trade Report & Entry and Exit Point Strategies - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Aug Rallies: Can NeuroPace Inc. stock deliver sustainable ROETrade Performance Summary & Weekly High Conviction Trade Ideas - ulpravda.ru

Dec 18, 2025

Lake Street Keeps Their Buy Rating on NeuroPace (NPCE) - The Globe and Mail

Dec 18, 2025

Dec 17, 2025

UBS Group Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - Defense World

Dec 17, 2025

NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment - Investing.com Nigeria

Dec 17, 2025

Is It Time To Consider Buying NeuroPace, Inc. (NASDAQ:NPCE)? - Yahoo Finance

Dec 17, 2025

NeuroPace Files FDA Application to Expand RNS System Use - marketscreener.com

Dec 17, 2025

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Investing News Network

Dec 17, 2025

UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating - marketscreener.com

Dec 16, 2025

UBS Group Raises NeuroPace (NASDAQ:NPCE) Price Target to $22.00 - MarketBeat

Dec 16, 2025

Dec 13, 2025

Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE) - The Globe and Mail

Dec 13, 2025

Dec 11, 2025

NeuroPace (NASDAQ:NPCE) Price Target Raised to $20.00 at JPMorgan Chase & Co. - Defense World

Dec 11, 2025

NeuroPace price target raised to $20 from $18 at JPMorgan - MSN

Dec 11, 2025

Dec 10, 2025

Bank Watch: How buybacks impact NeuroPace Inc stock value2025 Biggest Moves & AI Forecast Swing Trade Picks - moha.gov.vn

Dec 10, 2025

JP Morgan Raises Price Target for NPCE to $20.00, Maintains Over - GuruFocus

Dec 10, 2025

JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat

Dec 10, 2025

Dec 09, 2025

NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting - MSN

Dec 09, 2025

NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy - Investing.com UK

Dec 09, 2025

NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy By Investing.com - Investing.com South Africa

Dec 09, 2025

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - BioSpace

Dec 09, 2025

Dec 08, 2025

Neuropace shows 77% reduction in seizures - BioWorld MedTech

Dec 08, 2025

NeuroPace reports 77% seizure reduction in epilepsy device trial - Investing.com

Dec 08, 2025

NeuroPace reports 77% seizure reduction in epilepsy device trial By Investing.com - Investing.com Canada

Dec 08, 2025

Neuropace announces positive 18-month NAUTILUS trial results in idiopathic generalized epilepsy - marketscreener.com

Dec 08, 2025